Global Blood Therapeutics Inc (GBT) Insider Jung Choi Sells 3,000 Shares of Stock

Global Blood Therapeutics Inc (NASDAQ:GBT) insider Jung Choi sold 3,000 shares of the firm’s stock in a transaction on Tuesday, April 17th. The stock was sold at an average price of $45.50, for a total value of $136,500.00. Following the completion of the transaction, the insider now directly owns 137,677 shares of the company’s stock, valued at $6,264,303.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Jung Choi also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Friday, March 16th, Jung Choi sold 3,000 shares of Global Blood Therapeutics stock. The stock was sold at an average price of $54.15, for a total value of $162,450.00.
  • On Friday, February 16th, Jung Choi sold 3,000 shares of Global Blood Therapeutics stock. The stock was sold at an average price of $62.95, for a total value of $188,850.00.

NASDAQ:GBT traded up $0.10 during trading hours on Friday, hitting $43.10. 58,845 shares of the company’s stock traded hands, compared to its average volume of 1,011,273. Global Blood Therapeutics Inc has a 52 week low of $24.02 and a 52 week high of $68.05.

Global Blood Therapeutics (NASDAQ:GBT) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by ($0.22). equities research analysts anticipate that Global Blood Therapeutics Inc will post -3.78 EPS for the current year.

A number of large investors have recently bought and sold shares of the stock. Perceptive Advisors LLC raised its position in Global Blood Therapeutics by 14.7% during the fourth quarter. Perceptive Advisors LLC now owns 4,889,066 shares of the company’s stock valued at $192,384,000 after purchasing an additional 625,000 shares in the last quarter. Citadel Advisors LLC raised its position in Global Blood Therapeutics by 161.7% during the fourth quarter. Citadel Advisors LLC now owns 716,611 shares of the company’s stock valued at $28,199,000 after purchasing an additional 442,828 shares in the last quarter. RTW Investments LP raised its position in Global Blood Therapeutics by 2,186.9% during the fourth quarter. RTW Investments LP now owns 601,683 shares of the company’s stock valued at $23,676,000 after purchasing an additional 575,373 shares in the last quarter. Millennium Management LLC raised its position in Global Blood Therapeutics by 4,463.4% during the fourth quarter. Millennium Management LLC now owns 479,838 shares of the company’s stock valued at $18,882,000 after purchasing an additional 469,323 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in Global Blood Therapeutics by 2.4% during the fourth quarter. Geode Capital Management LLC now owns 340,951 shares of the company’s stock valued at $13,415,000 after purchasing an additional 7,875 shares in the last quarter. 85.41% of the stock is owned by institutional investors.

A number of research firms have recently commented on GBT. William Blair began coverage on Global Blood Therapeutics in a report on Tuesday, January 23rd. They issued an “outperform” rating and a $80.00 price target for the company. SunTrust Banks set a $80.00 price target on Global Blood Therapeutics and gave the stock a “buy” rating in a report on Thursday, March 1st. ValuEngine raised Global Blood Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. BidaskClub lowered Global Blood Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, April 4th. Finally, Cantor Fitzgerald set a $72.00 price objective on Global Blood Therapeutics and gave the company an “overweight” rating in a research note on Tuesday, February 27th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and twelve have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $70.69.

TRADEMARK VIOLATION WARNING: “Global Blood Therapeutics Inc (GBT) Insider Jung Choi Sells 3,000 Shares of Stock” was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this news story on another domain, it was stolen and republished in violation of US and international copyright laws. The correct version of this news story can be accessed at https://ledgergazette.com/2018/04/20/global-blood-therapeutics-inc-gbt-insider-jung-choi-sells-3000-shares-of-stock.html.

About Global Blood Therapeutics

Global Blood Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders. Its lead product candidate is voxelotor, an oral once-daily therapy that modulates hemoglobin's affinity for oxygen, which is in Phase 3 clinical trials in adult and adolescent patients with sickle cell disease (SCD), as well as in evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase 2a clinical trial of adolescent and pediatric patients with SCD.

Insider Buying and Selling by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply